Header Logo

Connection

MICHAEL JAMES OVERMAN to Microsatellite Instability

Back to Details
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Microsatellite Instability.
MICHAEL JAMES OVERMAN
Connection Strength
5.227
Microsatellite Instability
  1. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Immunother Cancer. 2024 May 31; 12(5).
    View in: PubMed
    Score: 0.797
  2. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 09; 18(9):1182-1191.
    View in: PubMed
    Score: 0.495
  3. Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. Eur J Cancer. 2024 Nov; 212:114336.
    View in: PubMed
    Score: 0.204
  4. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. Eur J Cancer. 2024 Mar; 199:113537.
    View in: PubMed
    Score: 0.194
  5. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023 11; 194:113356.
    View in: PubMed
    Score: 0.190
  6. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023 04 20; 41(12):2181-2190.
    View in: PubMed
    Score: 0.181
  7. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med. 2022 10 01; 146(10):1194-1210.
    View in: PubMed
    Score: 0.178
  8. Nivolumab?plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022 10; 33(10):1052-1060.
    View in: PubMed
    Score: 0.174
  9. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg. 2022 05 16; 109(6):489-492.
    View in: PubMed
    Score: 0.173
  10. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022 01 10; 40(2):161-170.
    View in: PubMed
    Score: 0.166
  11. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.164
  12. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. 2020 07; 31(7):861-872.
    View in: PubMed
    Score: 0.149
  13. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Clin Colorectal Cancer. 2020 06; 19(2):73-81.
    View in: PubMed
    Score: 0.148
  14. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 03; 19(1):48-56.e2.
    View in: PubMed
    Score: 0.145
  15. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019 11; 24(11):1453-1461.
    View in: PubMed
    Score: 0.141
  16. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709.
    View in: PubMed
    Score: 0.133
  17. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:239-247.
    View in: PubMed
    Score: 0.131
  18. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol. 2018 08; 14(18):1869-1874.
    View in: PubMed
    Score: 0.129
  19. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 03 10; 36(8):773-779.
    View in: PubMed
    Score: 0.128
  20. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. Cancer J. 2016 May-Jun; 22(3):190-5.
    View in: PubMed
    Score: 0.114
  21. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May; 25(5):1032-8.
    View in: PubMed
    Score: 0.098
  22. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7.
    View in: PubMed
    Score: 0.096
  23. High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol. 2013 Aug; 37(8):1192-200.
    View in: PubMed
    Score: 0.094
  24. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010 Jan 05; 102(1):144-50.
    View in: PubMed
    Score: 0.073
  25. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul; 35(7):643-655.
    View in: PubMed
    Score: 0.050
  26. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers. Eur J Cancer. 2024 Feb; 198:113495.
    View in: PubMed
    Score: 0.048
  27. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun. 2023 12 11; 3(12):2510-2517.
    View in: PubMed
    Score: 0.048
  28. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Oncologist. 2023 09 07; 28(9):771-779.
    View in: PubMed
    Score: 0.047
  29. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. J Clin Oncol. 2023 04 01; 41(10):1943-1948.
    View in: PubMed
    Score: 0.045
  30. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist. 2022 11 03; 27(11):952-957.
    View in: PubMed
    Score: 0.045
  31. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Eur J Cancer. 2022 09; 172:171-181.
    View in: PubMed
    Score: 0.044
  32. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer. 2022 02; 10(2).
    View in: PubMed
    Score: 0.042
  33. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. Eur J Cancer. 2022 01; 161:90-98.
    View in: PubMed
    Score: 0.042
  34. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clin Cancer Res. 2021 07 01; 27(13):3641-3648.
    View in: PubMed
    Score: 0.040
  35. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 03 02; 19(3):329-359.
    View in: PubMed
    Score: 0.040
  36. Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 02 01; 113(2):208-211.
    View in: PubMed
    Score: 0.040
  37. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670.
    View in: PubMed
    Score: 0.039
  38. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer. 2021 06; 20(2):137-147.e1.
    View in: PubMed
    Score: 0.039
  39. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010.
    View in: PubMed
    Score: 0.035
  40. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.032
  41. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol. 2017 Nov 01; 3(11):1546-1553.
    View in: PubMed
    Score: 0.032
  42. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.